| Literature DB >> 29615540 |
Valentina Rovella1, Giulia Marrone1,2, Mariarita Dessì3, Michele Ferrannini1, Nicola Toschi4,5, Antonio Pellegrino6, Maurizio Casasco7, Nicola Di Daniele1, Annalisa Noce1.
Abstract
Renal dysfunction is a risk factor for morbidity and mortality in cardiac surgery patients. Serum Cystatin C (sCysC) is a well-recognized marker of early renal dysfunction but few reports evaluate its prognostic cardio-vascular role. The aim of the study is to consider the prognostic value of sCysC for cardiovascular mortality. Four hundred twenty-four cardiac-surgery patients (264 men and 160 women) were enrolled. At admission, all patients were tested for renal function and inflammatory status. Patients were subdivided in subgroups according to the values of the following variables: sCysC, serum Creatinine (sCrea), age, high sensitivity-C Reactive Protein, fibrinogen, surgical procedures and Kaplan-Meier cumulative survival curves were plotted. The primary end-point was cardiovascular mortality. In order to evaluate the simultaneous independent impact of all measured variables on survival we fitted a multivariate Cox-Proportional Hazard Model (CPHM). In Kaplan-Meier analysis 124 patients (29.4%) reached the end-point. In multivariate CPHM, the only significant predictors of mortality were sCysC (p<0.00001, risk ratio: 1.529, CI: 1.29-1.80) and age (p=0.039, risk ratio: 1.019, CI: 1.001-1.037). When replacing sCysC with sCrea, the only significant predictor of mortality was sCrea (p=0.0026; risk ratio 1.20; CI: 1.06-1.36). Increased levels of sCysC can be considered a useful biomarker of cardiovascular mortality in cardiac-surgery patients.Entities:
Keywords: cardiac surgery; cardio-vascular mortality; cardiovascular biomarker; risk stratification; serum creatinine; serum cystatin C
Mesh:
Substances:
Year: 2018 PMID: 29615540 PMCID: PMC5892696 DOI: 10.18632/aging.101403
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Epidemiological features of study population.
| 67.70 ± 10.61* | |
| 264 males | |
| 160 females | |
| 23.2 ± 4.6* | |
| 85 | |
| 19.3 | |
| 23.1 | |
| 1.11±0.86* | |
| 71.01±21.55* | |
| 1.40±0.71* | |
| 58.04±23.54* |
*Data is expressed as mean ± Standard Deviation (SD)
Probability of survival related to laboratory parameters of kidney function and inflammation, type of surgical procedure and age.
| Range <0.81 | Range 0.81-1.20 (n=171) | Range 1.21-3.5 (n=214) | Range >3.5 (n=5) | |||
| Range <0.81 | Range 0.81-1.20 (n=214) | Range 1.21-3.5 (n=73) | Range >3.5 (n=8) | |||
| Range <3 | Range 3.1-6 (n=62) | Range 6.1-9 (n=26) | Range >9 (n=178) | S1vs S2 p= 0.301 | ||
| Range <351.38 | Range 351.38-555.05 | Range 555.06-758.73 | Range >758.63 | 0.06 | ||
| Sur 1 | Sur 2 | Sur 3 | Sur 4 | 0.263 | ||
| Range <41 | Range 41-56 | Range 57-72 | Range >72 | 0.184 |
Sur1= Isolated coronary artery bypass graft procedure
Sur2= Coronary artery bypass graft combined to valve replacement or repair procedure
Sur3= Valve replacement or repair procedure
Sur4= Other surgical procedures (septal defects closure, myxoma resection, atrial fibrillation ablation with Maze procedure)
Figure 1Kaplan-Meier analysis: mortality percentage in sCysC four subgroups: S1< 0.81 mg/l, S2= 0.81-1.20 mg/l, S3=1.21-3.5 mg/l and S4 >3.5 mg/l
Figure 2Kaplan-Meier analysis: mortality percentage in sCrea four subgroups: S1< 0.81 mg/dl, S2= 0.81-1.20 mg/dl, S3=1.21-3.5 mg/dl and S4 >3.5 mg/dl.
Probability of survival correlated with sex and diabetes.
| 260 | 156 | 0.091 | |
| 131 | 285 | 0.786 |